[Correspondence] Liraglutide for patients with non-alcoholic steatohepatitis
We read with great interest the results of the LEAN study,1 which compared the histological liver effect of liraglutide versus placebo in patients with non-alcoholic steatohepatitis. A greater resolution of non-alcoholic steatohepatitis and lesser fibrosis progression were seen in the liraglutide group than in the placebo group. The study is well designed and all the patients included had histological evidence of non-alcoholic steatohepatitis. Nevertheless, we were surprised that patients were overweight at screening, and that the mean body-mass index at baseline was very different between the liraglutide and placebo groups (34·2 kg/m2 [SD 4·7] vs 37·7 kg/m2 [6·2]), suggesting that patients were not matched for weight.